1
|
Abstract
Development of truly useful wearable physiologic monitoring devices for use in diabetes management is still in its infancy. From wearable activity monitors such as fitness trackers and smart watches to contact lenses measuring glucose levels in tears, we are just at the threshold of their coming use in medicine. Ultimately, such devices could help to improve the performance of sense-and-respond insulin pumps, illuminate the impact of physical activity on blood glucose levels, and improve patient safety. This is a summary of our experience attempting to use such devices to enhance continuous glucose monitoring-augmented insulin pump therapy. We discuss the current status and present difficulties with available devices, and review the potential for future use.
Collapse
Affiliation(s)
- Frank L. Schwartz
- Center for Diabetes and Endocrine Diseases, West Virginia University Medicine Camden Clark Medical Center, Parkersburg, WV, USA
- The Diabetes Institute, Ohio University, Athens, OH, USA
| | - Cynthia R. Marling
- The Diabetes Institute, Ohio University, Athens, OH, USA
- School of Electrical Engineering and Computer Science, Russ College of Engineering and Technology, Ohio University, Athens, OH, USA
- Cynthia R. Marling, School of Electrical Engineering and Computer Science, Russ College of Engineering and Technology, Ohio University, 321D Stocker Center, Athens, OH 45701, USA.
| | - Razvan C. Bunescu
- The Diabetes Institute, Ohio University, Athens, OH, USA
- School of Electrical Engineering and Computer Science, Russ College of Engineering and Technology, Ohio University, Athens, OH, USA
| |
Collapse
|
2
|
Abstract
BACKGROUND Hypoglycemia is often the limiting factor for intensive glucose control in diabetes management, however its actual prevalence in type 2 diabetes (T2DM) is not well documented. METHODOLOGY A total of 108 patients with T2DM wore a continuous glucose monitoring system (CGMS) for 5 days. Rates and patterns of hypoglycemia and glycemic variability (GV) were calculated. Patient and medication factors were correlated with rates, timing, and severity of hypoglycemia. RESULTS Of the patients, 49.1% had at least 1 hypoglycemic episode (mean 1.74 episodes/patient/ 5 days of CGMS) and 75% of those patients experienced at least 1 asymptomatic hypoglycemic episode. There was no significant difference in the frequency of daytime versus nocturnal hypoglycemia. Hypoglycemia was more frequent in individuals on insulin (alone or in combination) (P = .02) and those on oral hypoglycemic agents (P < .001) compared to noninsulin secretagogues. CGMS analysis resulted in treatment modifications in 64% of the patients. T2DM patients on insulin exhibited higher glycemic variability (GV) scores (2.3 ± 0.6) as compared to those on oral medications (1.8 ± 0.7, P = .017). CONCLUSIONS CGMS can provide rich data that show glucose excursions in diabetes patients throughout the day. Consequently, unwarranted onset of hypo- and hyperglycemic events can be detected, intervened, and prevented by using CGMS. Hypoglycemia was frequently unrecognized by the patients in this study (75%), which increases their potential risk of significant adverse events. Incorporation of CGMS into the routine management of T2DM would increase the detection and self-awareness of hypoglycemia resulting in safer and potentially better overall control.
Collapse
Affiliation(s)
- Richa Redhu Gehlaut
- Ohio University Heritage College of Osteopathic Medicine/O'Bleness Memorial Hospital, Diabetes Institute, Ohio University, Athens, OH, USA
| | - Godwin Y Dogbey
- Heritage College of Osteopathic Medicine/CORE Research Office, Ohio University, Athens OH, USA
| | | | - Cynthia R Marling
- School of Electrical Engineering and Computer Science, Russ College of Engineering and Technology and the Diabetes Institute, Ohio University, Athens, OH, USA
| | - Jay H Shubrook
- Touro University California, College of Osteopathic Medicine, Vallejo, CA, USA
| |
Collapse
|
3
|
Abstract
Clinical assessment of glycemic variability (GV) attempts to measure factors that may be contribute to tissue damage and the complications of diabetes that are not measured in glycosylated hemoglobin (HbA1C). Physicians managing patients with diabetes immediately understand the concept of GV; however, how it is assessed in clinical research trials and whether it has any predictive power in patients with type 1 diabetes is controversial and uncertain. This review is intended to help the reader understand the various GV metrics currently being reported in the literature, the potential mechanisms by which GV may contribute to the pathogenesis of the long-term complications of diabetes, and, finally, the evidence that reducing GV is beneficial to patients with type 1 diabetes.
Collapse
|
4
|
Schwartz FL, Marling CR. Use of Automated Bolus Calculators for Diabetes Management. Eur Endocrinol 2013; 9:92-95. [PMID: 29922360 DOI: 10.17925/ee.2013.09.02.92] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2013] [Accepted: 07/25/2013] [Indexed: 11/24/2022]
Abstract
Fewer than 30 % of patients with diabetes who are on insulin therapy achieve target glycated haemoglobin (HbA1C) levels. Automated bolus calculators (ABCs) are now almost universally used for patients on insulin pump therapy to calculate pre-meal insulin doses. Use of ABCs in glucose monitors and smart phone applications have the potential to improve glucose control in a larger population of individuals with diabetes on insulin therapy by overcoming the fear of hypoglycaemia and assisting those with low numeracy skills.
Collapse
Affiliation(s)
- Frank L Schwartz
- Professor of Endocrinology, The Diabetes Institute, Ohio University Heritage College of Osteopathic Medicine, Athens, Ohio, US
| | - Cynthia R Marling
- Associate Professor, School of Electrical Engineering and Computer Science, Russ College of Engineering and Technology, Ohio University, Athens, Ohio, US
| |
Collapse
|
5
|
Abstract
OBJECTIVE Glycemic variability (GV) is an important component of overall glycemic control for patients with diabetes mellitus. Physicians are able to recognize excessive GV from continuous glucose monitoring (CGM) plots; however, there is currently no universally agreed upon GV metric. The objective of this study was to develop a consensus perceived glycemic variability (CPGV) metric that could be routinely applied to CGM data to assess diabetes mellitus control. METHODS Twelve physicians actively managing patients with type 1 diabetes mellitus rated a total of 250 24 h CGM plots as exhibiting low, borderline, high, or extremely high GV. Ratings were averaged to obtain a consensus and then input into two machine learning algorithms: multilayer perceptrons (MPs) and support vector machines for regression (SVR). In silica experiments were run using each algorithm with different combinations of 12 descriptive input features. Ten-fold cross validation was used to evaluate the performance of each model. RESULTS The SVR models approximated the physician consensus ratings of unseen CGM plots better than the MP models. When judged by the root mean square error, the best SVR model performed comparably to individual physicians at matching consensus ratings. When applied to 262 different CGM plots as a screen for excessive GV, this model had accuracy, sensitivity, and specificity of 90.1%, 97.0%, and 74.1%, respectively. It significantly outperformed mean amplitude of glycemic excursion, standard deviation, distance traveled, and excursion frequency. CONCLUSIONS This new CPGV metric could be used as a routine measure of overall glucose control to supplement glycosylated hemoglobin in clinical practice.
Collapse
Affiliation(s)
- Cynthia R Marling
- School of Electrical Engineering and Computer Science, Russ College of Engineering and Technology, Ohio University, Athens, OH 45701, USA.
| | | | | | | | | |
Collapse
|
6
|
Abstract
The OneTouch® Verio™ IQ Meter with PatternAlert™ Technology has been approved by the U.S. Food and Drug Administration as the first self-glucose monitor that can automatically determine glycemic patterns [high and low pre-meal blood glucose (BG)] for health care providers (HCPs) and patients. In this issue of Journal of Diabetes Science and Technology, Katz and coauthors demonstrate that this device was more accurate and quicker in detecting abnormal glucose patterns than the review by HCPs of 30-day handwritten BG logs and that its interpretations were positively accepted by the HCPs. Continued development of automated pattern analysis and decision-support software to overcome the "data-overload" associated with intensive glucose monitoring and diabetes management will reduce clinical inertia and could dramatically improve diabetes outcomes.
Collapse
Affiliation(s)
- Frank L Schwartz
- Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio 45701, USA.
| | | | | |
Collapse
|
7
|
Schwartz FL, Guo A, Marling CR, Shubrook JH. Analysis of use of an automated bolus calculator reduces fear of hypoglycemia and improves confidence in dosage accuracy in type 1 diabetes mellitus patients treated with multiple daily insulin injections. J Diabetes Sci Technol 2012; 6:150-2. [PMID: 22401333 PMCID: PMC3320832 DOI: 10.1177/193229681200600118] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
In this issue of Journal of Diabetes Science and Technology, Barnard and colleagues evaluate the use of the ACCU-CHEK® Aviva Expert blood glucose meter/bolus advisor system in patients with type 1 diabetes mellitus. Hypoglycemia is a major limiting factor to intensive glucose control, and fear of hypoglycemia, especially in those who have experienced severe reactions, is a major barrier. The bolus advisor improved overall glucose control and increased adherence by overcoming the patients' fear of hypoglycemia, giving them more confidence to give adequate doses of insulin to control hyperglycemia. In this review, we discuss other human factors that become barriers to intensive control, which can benefit from new technologies, including numeracy literacy, information overload, time required for diabetes self-care, and device incompatibility.
Collapse
Affiliation(s)
- Frank L Schwartz
- Appalachian Rural Health Institute Diabetes/Endocrine Center at The Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA.
| | | | | | | |
Collapse
|
8
|
Abstract
OBJECTIVE Glycemic variability contributes to oxidative stress, which has been linked to the pathogenesis of the long-term complications of diabetes. Currently, the best metric for assessing glycemic variability is mean amplitude of glycemic excursion (MAGE); however, MAGE is not in routine clinical use. A glycemic variability metric in routine clinical use could potentially be an important measure of overall glucose control and a predictor of diabetes complication risk not detected by glycosylated hemoglobin (A1C) levels. This study aimed to develop and evaluate new automated metrics of glycemic variability that could be routinely applied to continuous glucose monitoring (CGM) data to assess and enhance glucose control. METHOD Individual 24 h CGM tracings from our clinical diabetes research database were scored for MAGE and two additional metrics designed to compensate for aspects of variability not captured by MAGE: (1) number of daily glucose fluctuations >75 mg/dl that leave the normal range (70-175 mg/dl), or excursion frequency, and (2) total daily fluctuation, or distance traveled. These scores were used to train machine learning algorithms to recognize excessive variability based on physician ratings of daily CGM charts, producing a third metric of glycemic variability: perceived variability. Finger stick A1C (average) and serum 1,5-anhydroglucitol (postprandial) levels were used as clinical markers of overall glucose control for comparison. RESULTS Mean amplitude of glycemic excursion, excursion frequency, and distance traveled did not adequately quantify the glycemic variability visualized by physicians who evaluated the daily CGM plots. A naive Bayes classifier was developed that characterizes CGM tracings based on physician interpretations of tracings. Preliminary results suggest that the number of excessively variable days, as determined by this naive Bayes classifier, may be an effective way to automatically assess glycemic variability of CGM data. This metric more closely reflects 90-day changes in serum 1,5-anhydroglucitol levels than does MAGE. CONCLUSION We have developed a new automated metric to assess overall glycemic variability in people with diabetes using CGM, which could easily be incorporated into commercially available CGM software. Additional work to validate and refine this metric is underway. Future studies are planned to correlate the metric with both urinary 8-iso-prostaglandin F2 alpha excretion and serum 1,5-anhydroglucitol levels to see how well it identifies patients with high glycemic variability and increased markers of oxidative stress to assess risk for long-term complications of diabetes.
Collapse
Affiliation(s)
- Cynthia R Marling
- School of Electrical Engineering and Computer Science, Russ College of Engineering and Technology, Ohio University, Athens, Ohio 45701, USA.
| | | | | | | | | |
Collapse
|
9
|
Schwartz FL, Vernier SJ, Shubrook JH, Marling CR. Evaluating the automated blood glucose pattern detection and case-retrieval modules of the 4 Diabetes Support System. J Diabetes Sci Technol 2010; 4:1563-9. [PMID: 21129354 PMCID: PMC3005069 DOI: 10.1177/193229681000400633] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND We have developed a prototypical case-based reasoning system to enhance management of patients with type 1 diabetes mellitus (T1DM). The system is capable of automatically analyzing large volumes of life events, self-monitoring of blood glucose readings, continuous glucose monitoring system results, and insulin pump data to detect clinical problems. In a preliminary study, manual entry of large volumes of life-event and other data was too burdensome for patients. In this study, life-event and pump data collection were automated, and then the system was reevaluated. METHODS Twenty-three adult T1DM patients on insulin pumps completed the five-week study. A usual daily schedule was entered into the database, and patients were only required to upload their insulin pump data to Medtronic's CareLink® Web site weekly. Situation assessment routines were run weekly for each participant to detect possible problems, and once the trial was completed, the case-retrieval module was tested. RESULTS Using the situation assessment routines previously developed, the system found 295 possible problems. The enhanced system detected only 2.6 problems per patient per week compared to 4.9 problems per patient per week in the preliminary study (p=.017). Problems detected by the system were correctly identified in 97.9% of the cases, and 96.1% of these were clinically useful. CONCLUSIONS With less life-event data, the system is unable to detect certain clinical problems and detects fewer problems overall. Additional work is needed to provide device/software interfaces that allow patients to provide this data quickly and conveniently.
Collapse
Affiliation(s)
- Frank L Schwartz
- Appalachian Rural Health Institute Diabetes and Endocrine Center, Ohio University College of Osteopathic Medicine, School of Electrical Engineering and Computer Science, Ohio University, Athens, Ohio 45701, USA
| | | | | | | |
Collapse
|
10
|
Abstract
BACKGROUND This study was conducted to develop case-based decision support software to improve glucose control in patients with type 1 diabetes mellitus (T1DM) on insulin pump therapy. While the benefits of good glucose control are well known, achieving and maintaining good glucose control remains a difficult task. Case-based decision support software may assist by recalling past problems in glucose control and their associated therapeutic adjustments. METHODS Twenty patients with T1DM on insulin pumps were enrolled in a 6-week study. Subjects performed self-glucose monitoring and provided daily logs via the Internet, tracking insulin dosages, work, sleep, exercise, meals, stress, illness, menstrual cycles, infusion set changes, pump problems, hypoglycemic episodes, and other events. Subjects wore a continuous glucose monitoring system at weeks 1, 3, and 6. Clinical data were interpreted by physicians, who explained the relationship between life events and observed glucose patterns as well as treatment rationales to knowledge engineers. Knowledge engineers built a prototypical system that contained cases of problems in glucose control together with their associated solutions. RESULTS Twelve patients completed the study. Fifty cases of clinical problems and solutions were developed and stored in a case base. The prototypical system detected 12 distinct types of clinical problems. It displayed the stored problems that are most similar to the problems detected, and offered learned solutions as decision support to the physician. CONCLUSIONS This software can screen large volumes of clinical data and glucose levels from patients with T1DM, identify clinical problems, and offer solutions. It has potential application in managing all forms of diabetes.
Collapse
Affiliation(s)
- Frank L. Schwartz
- Appalachian Rural Health Institute Diabetes and Endocrine Center, Ohio University College of Osteopathic Medicine, Ohio University, Athens, Ohio
| | - Jay H. Shubrook
- Appalachian Rural Health Institute Diabetes and Endocrine Center, Ohio University College of Osteopathic Medicine, Ohio University, Athens, Ohio
| | - Cynthia R. Marling
- School of Electrical Engineering and Computer Science, Russ College of Engineering and Technology, Ohio University, Athens, Ohio
| |
Collapse
|